Profile of Antihypertensive Drugs in Hypertensive Patients with Chronic Kidney Disease
Article Sidebar
Main Article Content
Page: 1912-1918
Abstract
Hypertension is one of the cardiovascular complications of chronic kidney disease (CKD). Control of blood pressure can prevent the progression of CKD and reduce the risk of cardiovascular complications. Antihypertensive drugs are required to control blood pressure. This study aimed to describe the profile of antihypertensive drug use in hypertensive patients with CKD. It was a retrospective study using medical records of hypertensive patients with CKD at Syarifah Ambami Rato Ebu Hospital, Bangkalan, from January 2019 to August 2021. This study was conducted between November 2021 and February 2022. The profile of antihypertensive drug use is shown descriptively. Forty-two hypertensive patients with CKD who met the inclusion criteria were included in this study, with more than 90% including end-stage kidney disease. Anemia is the most common complication in hypertensive patients with CKD. Loop diuretics (furosemide) and calcium channel blockers (nicardipine, amlodipine) are the most widely used antihypertensive drugs, with percentages of 28%, 25%, and 19%, respectively. The most commonly used antihypertensive combinations were furosemide + nicardipine by 46% and the combination of furosemide + candesartan + nifedipine by 43%. This study concludes that loop diuretics and calcium channel blockers are the most widely used antihypertensive drugs in hypertensive patients with CKD.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Indonesian Renal Registry. 11 Th Report Of Indonesian Renal Registry 2018. Diakes di https://www.indonesianrenalregistry.org/ tanggal 29 Mei 2023.
Ameer, Omar Z. 2022. “Hypertension in Chronic Kidney Disease: What Lies behind the Scene.” Frontiers in Pharmacology 13.
Chan, Christopher T. et al. 2019. “Dialysis Initiation, Modality Choice, Access, and Prescription: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney International 96(1): 37–47.
Chou Yu Hsiang and Yung Ming Chen. 2021. “Aging and Renal Disease: Old Questions for New Challenges.” Aging and Disease 12(2): 515–28.
Bura Ursula, Didik Hasmono, Siti Surdijati, Ruddy Hartono. 2017. “Studi Penggunaan Antihipertensi Angiotensin Receptor Blockers Terhadap Pasien Gagal Ginjal Kronik Stadium V di Rumah Sakit Bhayangkara Surabaya”. Journal of Pharmacy Science and Practice 4(2):88-95
Fandinata Selly Septi, Rizky Darmawan, Ninik Mas Ulfa, Deddy Aryanda Putra. 2023. “Changes in Mean Arterial and Blood Pressure in Using Nicardipine in Hypertensive Crisis Patients at the Hajj General Hospital Surabaya from August to December 2021.” Borneo Journal of Pharmacy 6(1): 79–86.
Fitzpatrick, Jesse K. et al. 2022. “Loop and Thiazide Diuretic Use and Risk of Chronic Kidney Disease Progression: A Multicentre Observational Cohort Study.” BMJ Open 12(1).
Fu, Edouard L. et al. 2020. “Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.” Circulation: Heart Failure 13(11): E007180.
Arifa Saniya, Mahalul Azam, Oktia Woro. 2017. “Faktor Yang Berhubungan Dengan Kejadian Penyakit Ginjal Kronik Pada Penderita Hipertensi Di Indonesia”. Jurnal MKMI 13(4):319-328
James, Paul A. et al. 2014. “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8).” JAMA 311(5): 507–20.
Ariyanto, Suharyo Hadisaputro, Lestariningsih, Sakundarno Ali, Selamat Budijitno. 2018. “Beberapa Faktor Risiko Kejadian Penyakit Ginjal Kronik (PGK) Stadium V Pada Kelompok Usia Kurang Dari 50 Tahun”. Jurnal Epidemiologi Kesehatan Komunitas 3(1):1-6
Kementerian Kesehatan Republik Indonesia. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar Republik Indonesia. 2018. Kementerian Kesehatan Republik Indonesia.
Magvanjav, Oyunbileg et al. 2019. “Antihypertensive Therapy Prescribing Patterns and Correlates of Blood Pressure Control among Hypertensive Patients with Chronic Kidney Disease.” Journal of Clinical Hypertension 21(1): 91–101.
National Kidney Foundation. 2002. Clinical Practice Guidelines for Chronic Kidney Disease : Evaluation, Classification and Stratification. National Kidney Foundation.
Ohno Shoko, Akira Ishii, Motoko Yanagita, and Hideki Yokoi. 2022. “Calcium Channel Blocker in Patients with Chronic Kidney Disease.” Clinical and Experimental Nephrology 26(3): 207–15.
Portolés, Jose, Leyre Martín, José Jesús Broseta, and Aleix Cases. 2021. “Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments to Future Agents.” Frontiers in Medicine 8.
Pradiningsih, Anna, Baiq Leny Nopitasari, Nur Furqani, and Esi Wahyuningsih. 2020. “Evaluasi Penggunaan Obat Antihipertensi Pada Pasien Gagal Ginjal Kronik Rawat Inap Di Rumah Sakit Umum Daerah Provinsi Nusa Tenggara Barat.” Jurnal Ilmu Kefarmasian 1(2).
Pugh, Dan, Peter J. Gallacher, and Neeraj Dhaun. 2019. “Management of Hypertension in Chronic Kidney Disease.” Drugs 79(4): 365–79.
Rachmaini Fitri, Lia Amalia, and Cherry Rahayu. 2020. “Profil Terapi Antihipertensi Dan Antihiperlipidemia Terhadap Fungsi Ginjal Pasien Diabetes Melitus Tipe 2 Dengan Komplikasi Penyakit Ginjal Kronis Di RSUP Dr. Hasan Sadikin” Pharmaceutical Sciences and Research 7(1): 17–27:17-27
Rasionalitas Penggunaan Diuretik pada Pasien Gagal Ginjal Kronik yang Dirawat Inap di RSUD Saiful Anwar Malang, Evaluasi, Jl M Kahfi II, Srengseng Sawah, and Jakarta Selatan. 2016. 9 Evaluation of Diuretic Rationalityon Chronic Renal Failure Inpatient at RSUD Dr. Saiful Anwar Malang.
Usmani Elisabeth Yuaninda, Ratih Tri Kusuma Dewi, and Evi Nurhayatun. 2022. “Perbandingan Kejadian Anemia Pada Pasien Penyakit Ginjal Kronis Dengan Hipertensi Terkontrol Dan Tidak Terkontrol.” Plexus Medical Journal 1(2): 60–67.
Zhang, Yaru et al. 2020. “ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials.” Drugs 80(8): 797–811.
Zhao, Mingming, et al. 2021. “Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis.” Frontiers in Pharmacology 12.
Zheng, Zhigui et al. 2021. “Continuous versus Intermittent Use of Furosemide in Patients with Heart Failure and Moderate Chronic Renal Dysfunction.” ESC Heart Failure 8(3): 2070–78.